"The voice for cancer physicians and their patients in Massachusetts."

FDA APPROVES Alectinib (Alecensa) for ALK Positive NSCLC

16 Nov 2017 10:46 AM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration granted regular approval to alectinib (Alecensa; Genentech) for the treatment of partients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. Read full press release. 

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software